Literature DB >> 1984074

Adenocarcinoma of the urachus associated with elevated levels of CA 125.

S Guarnaccia1, V Pais, J Grous, N Spirito.   

Abstract

Adenocarcinoma of the urachus is a rare genitourinary tumor with a poor prognosis. The treatment of choice is en bloc surgical resection, although combination therapy with surgery and chemotherapy has been used with mixed results. We describe a 69-year-old woman with adenocarcinoma of the urachus and elevated serum levels of CA 125 tumor marker. She was treated with resection plus 5-fluorouracil, doxorubicin and mitomycin, alternating with platinum-based chemotherapy. The serum CA 125 level decreased precipitously after the operation and became normal after 2 months of chemotherapy. The patient remained free of disease 1 year postoperatively. Serum CA 125 may be a useful tumor marker for urachal carcinoma and adjuvant chemotherapy may be effective in treating the disease.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1984074     DOI: 10.1016/s0022-5347(17)38271-x

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  9 in total

Review 1.  Primary urachal malignancy: case report and literature review.

Authors:  D Hayes Ryan; P Paramanathan; N Russell; J Coulter
Journal:  Ir J Med Sci       Date:  2013-05-16       Impact factor: 1.568

2.  A case of metastatic urachal adenocarcinoma treated with several different chemotherapeutic regimens.

Authors:  Christine Elser; Joan Sweet; Sendhil K Cheran; Masoom A Haider; Michael Jewett; Srikala S Sridhar
Journal:  Can Urol Assoc J       Date:  2012-02       Impact factor: 1.862

3.  Intra-abdominal mucinous adenocarcinoma of urachal origin: report of a case.

Authors:  Kotaro Hirashima; Ryojin Uchino; Shuichi Kume; Ken-ichi Iyama; Yumi Honda; Tsuguharu Asato; Hideo Baba
Journal:  Surg Today       Date:  2013-05-21       Impact factor: 2.549

4.  The utility of tumour markers in assessing the response to chemotherapy in advanced bladder cancer.

Authors:  A M Cook; R A Huddart; G Jay; A Norman; D P Dearnaley; A Horwich
Journal:  Br J Cancer       Date:  2000-06       Impact factor: 7.640

5.  Response to targeted therapy in urachal adenocarcinoma.

Authors:  Isabella Testa; Elena Verzoni; Paolo Grassi; Maurizio Colecchia; Filomena Panzone; Giuseppe Procopio
Journal:  Rare Tumors       Date:  2014-12-09

6.  Urachal carcinoma revealed by isolated hematuria.

Authors:  Issam Jandou; Adnan Ettanji; Ettaouil Mohammed; Amine Moataz; Dakir Mohammed; Adil Debbagh; Rachid Aboutaieb
Journal:  Ann Med Surg (Lond)       Date:  2021-02-25

Review 7.  Partial cystectomy for muscle-invasive bladder cancer: a review of the literature.

Authors:  Taylor C Peak; Ashok Hemal
Journal:  Transl Androl Urol       Date:  2020-12

8.  Urachal Carcinoma, An Unusual Possibility of Hematuria; Case Report and Literature Review.

Authors:  Răzvan Călin Tiutiucă; Alina Ioana Năstase Pușcașu; Elena Țarcă; Nicoleta Stoenescu; Elena Cojocaru; Laura Mihaela Trandafir; Viorel Țarcă; Dragoș-Viorel Scripcariu; Mihaela Moscalu
Journal:  Diagnostics (Basel)       Date:  2022-08-04

Review 9.  Biomarkers in Urachal Cancer and Adenocarcinomas in the Bladder: A Comprehensive Review Supplemented by Own Data.

Authors:  Henning Reis; Ulrich Krafft; Christian Niedworok; Orsolya Módos; Thomas Herold; Mark Behrendt; Hikmat Al-Ahmadie; Boris Hadaschik; Peter Nyirady; Tibor Szarvas
Journal:  Dis Markers       Date:  2018-03-12       Impact factor: 3.434

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.